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Abstract
Background: An organism’s immune response to a vaccine is dependent on a number of factors, including the site
of immunization. While muscle is the most common site for vaccine administration, other sites, including the
salivary gland, are poised to confer stronger and broader immunoprotection.
Findings: Studies exploring the salivary gland as an immunization site have involved protein antigens, as well as
live pathogens and DNA vaccines. While intraductal instillation of protein antigens into the salivary gland may result
in a relatively transient increase in antibody production, DNA or attenuated pathogen vaccination appear to confer
a lasting widespread mucosal immune response that includes robust salivary and enteric IgA, as well as high levels
of circulating IgG. Furthermore, vaginal and lung antibodies are also seen. For enteric pathogens, a common class
of pathogen encountered by travelers, this type of immune response provides for a level of redundant protection
against foreign microbes with mucosal targets.
Conclusion: The strength of immune response conferred by salivary gland vaccination is generally stronger than
that seen in response to the same vaccine at a comparison site. For example, where other routes fail, immunization
of the salivary gland has been shown to confer protection in lethal challenge models of infectious pathogens. A
host of vaccines currently under development suffer from immunogenicity challenges, adding to the widespread
interest and search for novel routes and adjuvants. With its capability to facilitate a strong and broad immune
response, the salivary gland warrants consideration as an immunization site, especially for vaccines with
immunogenicity challenges, as well as vaccines that would benefit from combined systemic and mucosal
immunity.
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Background
Vaccine delivery leading to systemic antibody-mediated
immunity is usually administered through intramuscular
injection (IM). Although the resulting humoral immune
response forms the basis for protection conferred by
nearly all vaccines delivered today, immune responses to
the vaccines for bacille Calmette-Guerin (tuberculosis)
and zoster trigger a strong cell-mediated immunity com-
ponent [1]. Most pathogens, however, enter the body
through mucosal tissues, including the aerodigestive and
urogenital tracts, the eye conjunctiva and external-
interfacing exocrine glands. Given the constant interaction
with the environment, the mucosal immune system has
evolved efficient mechanisms to maintain tolerance to-
ward self-antigens as non-pathogenic environmental anti-
gens, as well as mount active immune responses against
salient pathogens—features which make mucosal inter-
faces particularly attractive sites for vaccine delivery [2].
While most vaccines continue to be administered par-
enterally, a number of mucosal vaccines are commercially
available. The two routes of administration for the cur-
rently licensed mucosal vaccines are oral and nasal, and ex-
amples of orally-administered vaccines include vaccines for
rotavirus, poliovirus, and cholera [3]. Mucosal vaccines for
various influenza viruses are delivered intranasally, and a
recent exploratory clinical trial comparing a live attenuated
influenza vaccine (FluMist®) administered via the intranasal
or sublingual route reported haemagglutination inhibition
titers of 440 (n = 20) following intranasal delivery, and 380
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(n = 20) following sublingual delivery [4]. The administra-
tion site also affects the amount of compartmentalization
of the resulting mucosal immune response, with the sub-
lingual route leading to broader immune responses as
compared to oral and nasal administration [5]. Anatomic-
ally related to the sublingual route, another lesser-explored
mucosal vaccination route includes intraductal instillation
of the salivary gland.
There are three major bilateral salivary glands, the par-
otid, submandibular, and sublingual (collectively referred
to as the SG). They are encapsulated exocrine glands re-
sponsible for the manufacturing of saliva, a complex
fluid that includes significant amounts of peptides, pro-
teins, and carbohydrates. The SG is also an immune
organ, constantly coming in contact with external patho-
gens, and may be an optimal immunization site for certain
vaccines. In addition to containing dendritic cells, a type
of antigen presenting cell, the SG also appears to be a site
of B cell activation and isotype switching, along with in-
duction of antigen-specific cytotoxic T lymphocytes [6, 7].
Whole-cell killed pathogen immunization of the salivary
gland
Antibodies have long known to be present in saliva,
though they have largely been viewed as potential by-
product surrogate markers of exposure to various infec-
tious diseases [8–10]. Varying consistency across readings
and individuals has made the use of saliva as a diagnostic
a challenge. However, IgA from targeted SG secretions,
rather than whole saliva, has been shown to serve as
a high-sensitivity readout for enteric infections, in-
cluding enterotoxigenic Escherichia coli [11]. This will
likely become a useful proxy in field trials for vac-
cines targeting enteric pathogens given that collecting
and assaying targeted saliva is less resource-intensive
than intestinal lavages or fecal samples.
While immunizations at various sites can result in
measurable changes in salivary antibodies, both serum
and salivary antibodies have been reported to result from
repeated intraductal instillation of either protein or
formalin-fixed pathogen into the SG. One early study
found a strong IgA response following the injection of
bovine serum albumin (BSA) into surgically-exposed SG
[12]. However, the surgical procedure itself induces a
natural immune and inflammatory response, and injec-
tions via needles traverse the connective tissue sheathing
of the gland. A more direct and gentle route of ap-
plying a protein antigen was subsequently explored by
an Israeli group.
With an aim toward gaining a better understanding of
inflammatory processes in the parotid gland, the group
assessed locally-secreted antibodies in response to anti-
gen instillation of the parotid gland. Specifically, the
group investigated both salivary and systemic antibodies
resulting from intraductal instillation of BSA [13, 14].
The BSA was administered repeatedly a total of eight
times, and serum and saliva samples were assayed for
hemagglutinating anti-BSA antibodies. While they did
not evaluate the relative changes in IgAs and IgGs, an
increase in overall antibody titers of the saliva was seen.
However, they reported only approximately one third of
the animals had systemic hemagglutinating anti-BSA
antibodies, a result that may relate to the use of BSA as
the immunogen, which is a component in rodent food
pellets, and therefore a potential immune toleragen
[15, 16]. The ability for the SG to mount an immune
response to protein or protein subunit antigens con-
tinues to remain an open question.
Around the same time as the Israeli group was explor-
ing correlates of antigen-induced parotiditis, there was
broad scientific effort in trying to develop a vaccine for
dental caries, and specifically against the main offender,
Streptococcus mutans. Formalin-killed S. mutans was be-
ing injected by various routes by different groups in an
attempt to vaccinate various animal models from dental
caries, including intravenously and subcutaneously in the
mouth [17]. One group thought to investigate repeat intra-
ductal instillation of non-human primate parotid gland.
Following multiple oral subcutaneous immunization, the
group then instilled formalized S. mutans bilaterally into
the parotid glands of non-human primates [18]. While the
subcutaneous immunization (total of 10 repeat administra-
tions) led to modest increases in circulating IgM and IgG,
the same subcutaneous immunizations did not change sal-
ivary IgA. However, intraductal instillation significantly in-
creased both systemic IgG as well as salivary IgA. Buoyed
by the results, the same group followed up with a study to
assess efficacy (as measured by colonization), choosing to
focus on immunizing only via intraductal instillation [19].
Both the number of infected surfaces, as well as the num-
ber of S. mutans organisms in a particular plaque were re-
duced in the immunized group.
A study comparing multiple subcutaneous immuniza-
tions in the vicinity of the salivary glands with multiple
bilateral immunizations via intraductal instillation found
the subcutaneous route induced only a serum response
while intraductal instillation resulted in both serum and
salivary IgA responses [20]. This finding was then later
corroborated in a study instilling formalized S. mutans
three times in a single parotid [21]. While these results
were indeed promising, elevated specific antibody titers
did not last long; and a commercial vaccine that re-
quired routine boosting would be a challenge from a
commercial perspective. Live vaccines can confer more
enduring protection, but due to the safety concerns re-
lated to live vaccines, DNA vaccines present themselves as
promising alternatives, provided that any given DNA
vaccine is sufficiently immunogenic [22]. Immunogenicity,
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however, is one of the more common challenges associ-
ated with DNA vaccines, and in this regard, the SG may
have tempting appeal.
Genetic vaccination of the salivary gland
The first study to target the SG as a potential
immunization site using plasmid DNA (pDNA)
employed an expression system coding for Porphyromo-
nas gingivalis fimbriae [23]. Strong humoral and cell-
mediated immune responses were seen in BALB/c mice
following transcutaneous targeted salivary gland (TTSG)
immunization (see Table 1). Though similar systemic ti-
ters of IgG were seen in response to IM or TTSG
immunization, only TTSG elicited strong levels of saliv-
ary IgA. A more direct route of delivering a genetic vac-
cine to the SG was subsequently explored by a different
group using a plasmid coding for the influenza NP pro-
tein. In this pilot study, pDNA complexed with the cat-
ionic lipid reagent adjuvants GAP-DLRIE/DOPE or
Vaxfectin® was instilled intraductally into the SG in rats
[24]. While the authors were unable to detect changes in
salivary IgA, significant changes in systemic IgG were
observed.
A more extensive study, also done in rats, involved the
bilateral instillation of 88 μg of pDNA coding for either
of three antigens, human growth hormone (hGH), HIV
envelope protein gp120, or protective antigen (PA) from
Bacillus anthracis (i.e., anthrax) [25]. As compared to
IM and sublingual vaccination, higher titers of systemic
IgG (and IgA) were seen in response to SG vaccination
of plasmid encoding for hGH. Higher titers in response
to SG, rather than IM, vaccination were observed for the
gp120 genetic vaccine as well, and a memory response
was observed. Circulating antibodies titers in response
to SG and subcutaneous vaccination were more than
ten-fold higher than those seen in response to IM vac-
cination with the PA gene; and the higher titers (but not
the lower titers seen following IM vaccination) provided
protection from a subsequent lethal anthrax challenge.
Of particular interest to those involved in the
Table 1 A summary of various experiments using the Salivary Gland as an immunization site
Antigen IgA, saliva IgG, systemic Reference Model Notes
Formalized
S. mutans
++++ ++++ [18] NHP SGid > SC; Greater IgA and IgG seen with SGid imzn
than with SC imzn.
Formalized
S. mutans
+++ +++ [21] NHP Greater IgA seen with SGid imzn than with SC imzn.
Formalized
S. mutans




++++ +++ [20] NHP SGid immunization was strain specific.
Bovine serum albumin ++a ++a [13] Rats SGid; Moderate salivary and systemic antibody responses
reported
Bovine serum albumin ++a +a [14] Rats Multiple SGid BSA imzns are followed by systemic
antibodies.
MCMV, tcMCMV n.a. ++++ [33] Mice SGig imzn resulted in protection from viremia; IP
imzn did not.
MCMV, tcMCMV +++ +++ [7] Mice SGig > IP; Greater IgA and IgG seen with SGig imzn than
with IP imzn.
Adenovirus +++ ++++ [15] Rats SGid; Repeated pre-exposure to inactivated adenovirus
induced immune tolerance.
tcMCMV +++ ++++ [34] Mice SGid imzn resulted in protection from a lethal challenge.
pDNA: fimbriae from
P. ginigivalis
++++ +++ [23] Mice TSG > IM; Greater IgA seen with TSG imzn, than with IM
imzn. TSG and IM imzns resulted in equal IgG.
pDNA: influenza NP protein n.c. +++ [24] Rats SGid; Included testing of two adjuvants.
pDNA: NP protein, hGH,
gp120, anthrax PA
++++ ++++ [25] Rats SGid > IM; Greater IgA and IgG seen with SGid imzn than with
IM imzn. SG imzn protected from a lethal challenge; IM imzn
did not; distal mucosal response seen.
pDNA: gp120 +++ +++ [27] Rats, dogs SGid > IM (ASCs from Peyer’s patches); distal mucosal IgA
response seen in lungs.
Abbreviations: SGid intraductal instillation of the salivary gland, SGig direct injection into the gland through a small incision, TSG targeted injection of the salivary
gland, SC subcutaneous injection, IM intramuscular injection, IP intraperitoneal injection, imzn immunization, ASC antibody secreting cell, NHP non-human primate,
MCMV murine cytomegalovirus, tcMCMV tissue-cultured MCMV (i.e., attenuated MCMV), anthrax PA anthrax protective antigen, hGH human growth hormone,
gp120 HIV gp120, pDNA plasmid DNA, n.c. no change, n.a. not addressed. aAntibody response confounded by immunogen being present in animal chow, possibly
inducing immune tolerance; see [15, 16]. Table compiled by searching the PubMed database on “instillation duct antibodies” or “intraductal instillation antibodies,”
analyzing salient peer-reviewed reports and their references, then subjecting those reports to a citation tracking database (Web of Science®) and analyzing the
resulting reports, which were also run through a citation tracking database, with the salient reports evaluated as well
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development of novel mucosal vaccines were the obser-
vations of widespread mucosal antibody responses and
significant increases in salivary and fecal IgA, as well as
lung and vaginal IgG following SG vaccination with
gp120 combined with a Zn/lipid adjuvant. Antibody-
secreting cells (ASCs) isolated from Peyer’s patches fol-
lowing SG vaccination were approximately four times
higher than those seen following IM vaccination. As
antibody titer can predict efficacy, even for cell-mediated
immunity, these results suggest it would be prudent to
include the SG as a possible vaccination site [26].
Lastly, in an effort to explore the scalability of intra-
ductal instillation of a DNA vaccine to larger animals,
the method was extended to beagles in a follow-up study
[27]. Solutions containing pDNA in the presence of Zn
(with or without lipid) were instilled into the SG of the
rats and beagles. The rats and dogs received bilateral in-
stillations of 88 μg and 2.5 mg of pDNA, respectively,
and the resulting antibody titers following SG vaccin-
ation were similarly high, registering at above 10,000.
Addition of Zn improved protein expression, and a distal
IgA response was also measured in the lungs. ASCs
from Peyer’s patches were evaluated in this study as well,
and SG immunization was seen to result in approxi-
mately 3–4 times as many ASCs as compared to IM
immunization. Furthermore, there have been many de-
scribed improvements related to the vector design of
DNA vaccines, and optimizing future plasmids for instil-
lation would only further enhance effectiveness [28].
Collectively, the data suggest the SG may warrant inclu-
sion as a test vaccination route for mucosal vaccines
under development, especially DNA vaccines that would
benefit from increased immunogenicity.
Live pathogen vaccination of the salivary gland
Though the SG is a well-established effector site for
antibody-secreting B cells, induction of B cells is gener-
ally more restricted to specific sites, such as mucosa-
associated lymphoid tissue of the ileum [29]. However,
infiltrating leukocytes in other tissues (including SG) can
form ectopic lymphoid-like structures, including orga-
nized aggregates that promote antigen-specific adaptive
immune responses to include the proliferation of B cells
and the production of antigen-specific antibodies [30].
In response to an immune challenge, the SG can form
ectopic lymphoid-like structures that serve as inductive
sites and which express activation-induced cytidine de-
aminase (AID), an enzyme required for somatic hyper-
mutation and class switching [7]. This understanding
helps explain what happens when mechanisms get misa-
ligned, as in Sjogren’s syndrome, as well as the oppor-
tune results from studies instilling live pathogens [31].
Vaccination using live pathogens has long been dem-
onstrated to elicit broad and lasting immune responses.
Indeed, the first vaccines administered were all live [32].
In an effort to explore distal immune responses follow-
ing SG inoculation, one study investigated tissue viral ti-
ters, tissue pathology, and antibody responses. The
inoculum consisted of either murine cytomegalovirus
(MCMV) or the less virulent tissue-culture-derived
MCMV (tcMCMV) delivered through various routes, in-
cluding injecting into the salivary gland through a small
incision (intraglandular) [33]. While systemic IgG and
IgM observed in response to intraglandular and intraperi-
toneal inoculation were similar, of all the routes tested (in-
traperitoneal, intranasal, periglandular and intraglandular),
only intraglandular SG inoculation of tcMCMV was able
to prevent splenic necrosis and hepatitis while limit-
ing SG viral titers. Delivering tcMCMV into the SG
was also shown to correlate with maintaining SG
leukocyte infiltrates.
A subsequent comprehensive study by the same group
employed the gentler route of intraductal instillation.
Here, instilling either a replication-deficient recombinant
adenovirus expressing individual MCMV genes or
tcMCMV resulted in protection against a lethal systemic
challenge with MCMV [34]. Due to its broad tropism
and relative safety, the adenovirus is a common vector
used to deliver vaccine antigens and other transgenes,
and its potent immune reactions in the SG can be tolar-
ized through pre-exposure [35]. Using a recombinant
replication-deficient adenovirus to deliver MSMV genes
resulted in strong systemic neutralizing MCMV-specific
IgG in the serum [34]. Additionally, immunization with
the adenovirus induced mucosal neutralizing MCMV-
specific IgA at the primary immunization site (saliva), as
well as distal mucosal sites (feces and vagina). This ob-
servation further corroborated and extended the findings
by Tucker et al 2003, that SG vaccination with pDNA
results in distal mucosal immune responses. Lastly, these
immune responses provided vital protection in a lethal
MCMV challenge. In light of the strong mucosal and
systemic protective responses, the findings support the
further testing of the salivary gland as a potentially at-
tractive platform for active vaccine delivery.
Conclusion
Here we have attempted to provide an overview of the SG
as an immunization site, and synthesize a number of stud-
ies suggesting it be included as a selected immunization
site in the development of novel vaccines, especially vac-
cines that do not elicit strong immune responses. Table 1
provides a qualitative analysis of salivary and systemic
antibody responses following immunization of the salivary
gland in several animal models. Antibody responses were
measured by a host of methods, including hemagglutinat-
ing antibody titers, indirect immunofluorescent staining of
the immunogen, ELISA optical density, and percent
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specific antibody values measured by radioimmunoassay,
and a general qualitative magnitude of systemic IgG and
salivary IgA response is provided.
As shown in the Table, various groups have demon-
strated the SG to be capable of eliciting robust wide-
spread mucosal and systemic protective responses in
following antigen presentation, routinely resulting in
antibody titers higher than those seen with other
immunization targets. It is notable that studies have gen-
erally instilled the particular immunogen or vector (e.g.
formalized S. mutans, BSA, virus, or plasmid DNA) in
the absence of an adjuvant, yet still observed significant
immune responses. Indeed, while complete Freund’s ad-
juvant has been used in studies employing subcutaneous
immunizations delivered in the vicinity of the salivary
glands (reviewed in [17]), very few studies using intra-
ductal instillation have included potential immune adju-
vants in the infusate (cationic lipid transfection reagents
Vaxfectin® and GAP-DLRIE/DOPE in rats, or azo dye
Evans blue in dogs) [24, 27]. Studies have generally in-
stilled the test vaccine in a saline vehicle, achieving not-
able immune responses in the absence of an adjuvant.
Given that vaccine efficacy is typically linked to antibody
titer concentration, achieving high titers would be a
common goal. A host of groups are exploring novel ad-
juvants to enhance immunogencitiy, the needs of which
may be diminished if the vaccination site were able to fa-
cilitate a strong enough immune response.
While intraductal instillation into the SG is not an obvi-
ous route for vaccination, the potential benefits seen by a
robust immune response would warrant the additional re-
search effort. The practicality of mass immunization via
the SG may be logistically challenging. However, infusion
of the gland is a relatively simple procedure that can be
done in an outpatient setting, such as during a routine
dental check-up. While intraductal instillation is quick
and painless, requiring neither needles nor anesthesia,
most health-care workers have only modest familiarity
with the procedure; and so training and instrumentation
advances that simplify vaccine administration would
significantly increase the amenability of the SG as a
preferred site.
Additionally, saliva contains a number of carbohy-
drates, peptides, and enzymes, and this complex mixture
may require novel formulation approaches to maximize
vaccine efficiency and bring an SG-based vaccine into
practical application. While the infusate vehicle in most
SG immunization studies has been either water or a sim-
ple saline solution, the inclusion of mucoadhesives, pro-
tease, or nuclease inhibitors could further increase
immunization efficiency. For example, adding zinc to the
ductal infusate has been reported to result in a 20-fold
increase in transgene expression, which would be im-
portant for DNA-based vaccines [36]. Nevertheless, the
studies described above demonstrate striking capabilities
of the SG as an immunization site. There are currently a
host of antigen-based mucosal vaccines under develop-
ment using live-attenuated pathogens, as well as DNA-
based, carbohydrate, and protein antigens. While further
studies are certainly needed to build upon the current
literature discussed here, and specifically to compare SG
intraductal instillation with other administration tech-
niques into other tissues, the SG presents as an attract-
ive route of administration.
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